Merck KGaA heads the rat pack as OMT does antibodies its way
This article was originally published in Scrip
Executive Summary
The small, private biotechnology firm Open Monoclonal Technology (OMT) has entered into its first Big Pharma partnership – a deal with Merck KGaA – under the Palo Alto, California company's business plan to farm out its transgenic rats to companies looking to develop fully human monoclonal antibodies.